Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus...
Колбин А. С., Шестакова М. В., Галстян Г. Р., Жао W., Мосикян А. А., Курyлев А. А., Балyкина Y. Е., Проскурин М. А., Алексеева Y. Г., Старцева Е. Y.
Проблемы эндокринологии
Т. 63, Вып. 5, С. 307-319
Опубликовано: 2017
Тип ресурса: Статья
DOI:10.14341/probl2017635307-319
Аннотация:
Background. Type 2 diabetes mellitus (T2DM) and its complications are the major causes of long-term disability, significant performance loss, and premature mortality. Poor glycemic control, diabetes-related complications, and insulin therapy are associated with a significant increase in diabetes costs. The high cost of insulin analogues restricts reimbursement of their costs in some countries. Comprehensive clinical and economic assessments of different insulin analogues are the useful tool that may help policy-makers to set priorities in medicine provision within the existing system of healthcare funding. Aim - to compare the clinical and economic effectiveness of insulin degludec (100 U/mL) and insulin glargine (100 U/mL) in basal-bolus therapy for T2DM. Material and methods. Economic evaluation was based on cost effectiveness analysis (CEA), incremental cost-effectiveness ratio (ICER), cost effectiveness modelling (using 5-year time horizon), sensitivity analysis, and economic feasi
Ключевые слова:
Cost-effectiveness; Evaluation of health technologies; Insulin degludec; Pharmacoeconomic effectiveness.; Type 2 diabetes mellitus
Язык текста: Русский
ISSN: 2308-1430
Колбин А. С.
Шестакова М. В. Марина Владимировна 1962-
Галстян Г. Р. Гагик Радикович 1964-
Жао W.
Мосикян А. А.
Курyлев А. А.
Балyкина Y. Е.
Проскурин М. А.
Алексеева Y. Г.
Старцева Е. Y.
Kolbin A. S.
Shestakova M. V. Marina Vladimirovna 1962-
Galstyan G. R. Gagik Radikovich 1964-
Zhao W.
Mosikyan A. A.
Kurylev A. A.
Balykina Y. E.
Proskurin M. A.
Alekseeva Y. G.
Startseva E. Y.
Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy
Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus...
Текст визуальный непосредственный
Проблемы эндокринологии
Издательство Медиа Сфера
Т. 63, Вып. 5 С. 307-319
2017
Статья
Cost-effectiveness Evaluation of health technologies Insulin degludec Pharmacoeconomic effectiveness. Type 2 diabetes mellitus
Background. Type 2 diabetes mellitus (T2DM) and its complications are the major causes of long-term disability, significant performance loss, and premature mortality. Poor glycemic control, diabetes-related complications, and insulin therapy are associated with a significant increase in diabetes costs. The high cost of insulin analogues restricts reimbursement of their costs in some countries. Comprehensive clinical and economic assessments of different insulin analogues are the useful tool that may help policy-makers to set priorities in medicine provision within the existing system of healthcare funding. Aim - to compare the clinical and economic effectiveness of insulin degludec (100 U/mL) and insulin glargine (100 U/mL) in basal-bolus therapy for T2DM. Material and methods. Economic evaluation was based on cost effectiveness analysis (CEA), incremental cost-effectiveness ratio (ICER), cost effectiveness modelling (using 5-year time horizon), sensitivity analysis, and economic feasi